Elute, Inc. is an emerging leader in the development of patented drug-eluting devices with controlled and sustained therapeutic release. Their focus lies in addressing unmet clinical needs, particularly in the field of orthopedic infections, through the translation of science into novel products. With their revolutionary technology platform, they are dedicated to transforming patient care by enabling individuals to lead active, rich, and fulfilling lives. As a clinical-stage company, Elute, Inc. is currently engaged in a pioneering clinical study that aims to restore bone loss and reduce recurrent infections. Their unique bone void fillers exhibit 8 weeks of local antibiotic delivery, specifically designed to treat periprosthetic joint infections. With a distinguished team of experts and a commitment to advancing patient care, Elute, Inc. is at the forefront of developing a new class of bone void fillers that have the potential to make a significant impact in the field of orthopedics.Generated from the website